News Releases | LumiraDx

Year

11 Aug '22

LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18

LONDON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX ), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 18 th , 2022. On the day of the release, LumiraDx will host a conference call

11 Aug '22

LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18

LONDON , Aug. 11, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX ), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 18 th , 2022. On the day of the release, LumiraDx will host a conference call

25 Jul '22

LumiraDx to Present on Impact of its Next-Generation Microfluidic Technology at American Association for Clinical Chemistry (AACC) Annual Conference in Chicago

Company to host industry workshop describing key differentiators of its SARS-CoV-2 Ag test versus other rapid antigen tests in the market and how these factors influence use-case deployment Company to also be featured in two poster abstracts and will be exhibiting on show floor with demonstrations

21 Jul '22

LumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private Placement

LONDON , July 21, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced the pricing of its underwritten public offering of 43,000,000 common shares at a price to the public of $1.75 per share.

19 Jul '22

LumiraDx Announces Proposed Public Offering of Common Shares

LONDON , July 19, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced that it has commenced an underwritten public offering of 40,000,000 common shares. All of the shares in the proposed offering are to be sold by LumiraDx

09 Jun '22

LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System

Next-generation antigen test system built on more than eight years of research and backed by industry leading microfluidic experts The Amira System includes the Amira Analyzer, Amira SARS-CoV-2 Ag test strips, swabs and sample preparation materials Designed to provide lab-comparable performance at

08 Jun '22

LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete

LONDON , June 8, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX) today announced that it has achieved CE Mark for two new Fast Lab Solutions molecular tests, including Dual-Target SARS-CoV-2 STAR Complete and SARS-CoV-2 & Flu A/B RNA STAR Complete .

02 Jun '22

LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test

The LumiraDx NT-proBNP and the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test. Run on the highly portable LumiraDx Platform, they are designed for near-patient testing with connected results in 12 minutes and 6 minutes, respectively The

26 May '22

LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform

Rapid microfluidic immunofluorescence assay intended for the monitoring of individuals with diabetes, and as an aid in screening and identifying patients who may be at risk for developing diabetes The automated, quantitative fingerstick assay is run on the highly portable LumiraDx Platform and

20 May '22

LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test

LONDON , May 20, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, announced today that its rapid COVID-19 antigen assay, LumiraDx SARS-CoV-2 Ag Test has successfully received the Emergency Use Listing (EUL) by the World Health Organization (

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page